Cabaletta Bio Reports Third Quarter 2021 Financial Results and Provides Business Update
November 01, 2021 07:05 ET
|
Cabaletta Bio
– Dose dependent increase in DSG3-CAART persistence observed in the third dose cohort with 500 million DSG3-CAART cells relative to the first two low dose cohorts in DesCAARTes™ Phase 1 clinical trial...
Cabaletta Bio Reports Clinical Data from the Third Dose Cohort in DesCAARTes™ Trial in Patients with mPV
November 01, 2021 07:00 ET
|
Cabaletta Bio
– Dose dependent increase in DSG3-CAART persistence observed in the third dose cohort relative to the first two low dose cohorts throughout the 28 days following infusion – – No dose-limiting...
Cabaletta Bio Announces Presentation of Preclinical Data Supporting PLA2R-CAART as a Potential Precision Therapy for Antigen-Specific B Cell Depletion in PLA2R Membranous Nephropathy at ASN Kidney Week 2021
October 15, 2021 16:30 ET
|
Cabaletta Bio
– Chimeric AutoAntibody Receptor (CAAR) T cells specifically recognized and eliminated anti-PLA2R antibody-expressing B cells in vitro – – Membrane proteome arrays screened with PLA2R CAAR candidates...
Cabaletta Bio to Present at the Chardan 5th Annual Genetic Medicines Conference
September 28, 2021 08:00 ET
|
Cabaletta Bio
PHILADELPHIA, Sept. 28, 2021 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies...
Cabaletta Bio Announces Appointment of Michael Gerard as General Counsel
September 07, 2021 08:00 ET
|
Cabaletta Bio
PHILADELPHIA, Sept. 07, 2021 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies...
Cabaletta Bio to Participate in Upcoming Investor Conferences in September
September 02, 2021 08:00 ET
|
Cabaletta Bio
PHILADELPHIA, Sept. 02, 2021 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies...
Cabaletta Bio Reports Clinical Data from the Second Dose Cohort in DesCAARTes™ Trial in Patients with mPV
August 18, 2021 07:00 ET
|
Cabaletta Bio
– No dose-limiting toxicities (DLTs) or clinically relevant adverse events observed as of August 17 using 100 million cells in the second dose cohort – – DSG3-CAART persistence observed in all three...
Cabaletta Bio Reports Second Quarter 2021 Financial Results and Provides Business Update
August 05, 2021 07:30 ET
|
Cabaletta Bio
– Company continues to make progress on the DesCAARTes™ trial for DSG3-CAART; expects to report second and third cohort safety data in 3Q21 and 4Q21, respectively, and data on target engagement...
Cabaletta Bio Appoints Biopharmaceutical Leader Scott Brun, M.D. to Board of Directors
June 28, 2021 08:00 ET
|
Cabaletta Bio
Dr. Brun’s early and late-stage clinical development expertise in autoimmune, neurologic, and renal disease areas aligns well with Cabaletta’s rapidly emerging pipeline PHILADELPHIA, June 28, 2021 ...
Cabaletta Bio to Present at the Jefferies Healthcare Conference
May 27, 2021 08:00 ET
|
Cabaletta Bio
PHILADELPHIA, May 27, 2021 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies for...